Poster 13: Tirzepatide as a novel therapeutic option for patients with type 2 diabetes: a pooled analysis of SURPASS 1-5 trials

Aim: To evaluate the impact of patients' characteristics on the efficacy and the safety of subcutaneous tirzepatide once-weekly in patients with uncontrolled type 2 diabetes mellitus (T2DM).

Methods: This post hoc analyses of pooled SURPASS 1-5 randomised controlled trials examined changes from baseline in HbA1c and body weight and the proportions of patients who achieved the endpoint composite HbA1c with tirzepatide (5 mg, 10 mg and 15 mg) across the following subgroups; baseline HbA1c (> 7.5%-8.0%, > 8.0%-8.5% and > 8.5%-9.0%), baseline diabetes durations (< 5 years, 5-10 years and > 10 years), and age (non-elderly < 60 years and elderly > 60 years). 

Results: Based on diabetes duration, the mean HbA1c reduced from baseline (-1.87 % to -2.24% for tirzepatide 5 mg [P = 0.308], -1.89 % to -2.43 % with tirzepatide 10 mg [P = 0.015], and -2.07 % to -2.58 % with tirzepatide 15 mg [P = 0.010]. Similar reductions were observed in body weight with tirzepatide 5 mg (-5.4 kgs to 7.6 kgs, P = 0.247),  with tirzepatide 10 mg (-7.5 kgs to -10.7 kgs, P = 0.931) and with tirzepatide 15 mg (-8.8 kgs to -12.9 kgs, P = 0.959). Moreover, 78-93% of patients achieved a HbA1c <7% with tirzepatide vs 12-79% with comparators, 66-86% achieved HbA1c < 6.5% with tirzepatide vs 8-64% with comparators, and 23-50% achieved HbA1c < 5.6% with tirzepatide versus 1-19% in comparators. Similar patterns of reductions in HbA1c and body weight were observed across other subgroups (baseline HbA1c and age).

Conclusion: Tirzepatide was consistently efficacious and safe in the broad spectrum of patients with T2DM subgroups across the SURPASS 1-5 trials.